Leptomeningeal metastases in glioma: The Memorial Sloan Kettering Cancer Center experience Journal Article


Authors: Andersen, B. M.; Miranda, C.; Hatzoglou, V.; DeAngelis, L. M.; Miller, A. M.
Article Title: Leptomeningeal metastases in glioma: The Memorial Sloan Kettering Cancer Center experience
Abstract: OBJECTIVE: To perform a retrospective analysis examining the incidence and prognosis of glioma patients with leptomeningeal disease (LMD) at Memorial Sloan Kettering Cancer Center over a 15-year period and correlate these findings with clinicopathologic characteristics. METHODS: We conducted a retrospective review of glioma patients with LMD at Memorial Sloan Kettering Cancer Center diagnosed from 2001 to 2016. Patients were identified through a keyword search of their electronic medical record and by ICD-9 codes. RESULTS: One hundred three patients were identified with disseminated LMD and 85 patients with subependymal spread of disease, 4.7% of all patients with glioma. These cohorts were analyzed separately for time to development of disseminated LMD/subependymal LMD, median overall survival, and survival from LMD diagnosis. Patients were pooled for subsequent analyses (n = 188) because of comparable clinical behavior. LMD was present at glioma diagnosis in 10% of patients. In the remaining 90% of patients diagnosed at recurrence, time to LMD diagnosis, survival after LMD diagnosis, and overall survival varied by original histology. Patients with oligodendroglioma had a median survival of 10.8 (range 1.8-67.7) months, astrocytoma 6.5 (0.1-28.5) months, and glioblastoma 3.8 (0.1-32.6) months after LMD diagnosis. In addition, we found that treatment of LMD was associated with superior performance status and increased survival. CONCLUSION: Patients with LMD diagnosed at relapse may not have decreased overall survival as compared to historical controls with parenchymal relapse and may benefit from treatment. © 2019 American Academy of Neurology.
Journal Title: Neurology
Volume: 92
Issue: 21
ISSN: 0028-3878
Publisher: Lippincott Williams & Wilkins  
Date Published: 2019-05-21
Start Page: e2483
End Page: e2491
Language: English
DOI: 10.1212/wnl.0000000000007529
PUBMED: 31019097
PROVIDER: scopus
PMCID: PMC6541431
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Alexandra Miller
    74 Miller